Literature DB >> 2178911

The use of vasopressin in the treatment of upper gastrointestinal haemorrhage.

D L Stump1, T C Hardin.   

Abstract

Vasopressin is a potent vasoconstrictor which greatly reduces mesenteric blood flow. In patients with portal hypertension this results in decreased portal venous flow and portal pressure. Because of this property, vasopressin has been used for years in the therapy of variceal haemorrhage. A few controlled trials show that vasopressin causes a decrease in bleeding but has no effect on survival. It has been shown that intravenous vasopressin is just as effective as intra-arterial, and is associated with fewer complications. The inability to influence the outcome of variceal haemorrhage significantly may be related to suboptimal dosing due to the occurrence of systemic complications at higher doses. The combination of vasopressin with either sodium nitroprusside or nitroglycerin (glyceryl trinitrate) has resulted in a further decline of portal pressure, along with amelioration of most of the adverse haemodynamic effects of vasopressin. Whether or not clinical efficacy is increased when vasopressin is combined with sodium nitroprusside or nitroglycerin remains to be proven. Analogues of vasopressin, such as terlipressin, held early promise as agents which would be as effective as vasopressin, without the cardiac adverse effects. Recent data have not supported this and at present there is little to suggest any advantage of terlipressin over vasopressin. Virtually no adequate studies have yet been performed to support the use of vasopressin in the treatment of non-variceal haemorrhages. There is reason to suspect that vasopressin can effectively control bleeding from haemorrhagic gastritis, but the subsequent results of inducing gastric ischaemia in an already damaged gastric mucosa are unknown. In summary, vasopressin appears to have little effect on the mortality of patients with variceal haemorrhage. It may, however, help control the haemorrhage in some patients by lowering the portal pressure. Cardiovascular complications limit the dose that can be used but it is hoped that by combining vasopressin with nitroglycerin, a more effective and safe therapy will be available for variceal haemorrhages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178911     DOI: 10.2165/00003495-199039010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  107 in total

1.  A study of the effect of vasopressin on portal and systemic blood pressure.

Authors:  R EDMUNDS; J P WEST
Journal:  Surg Gynecol Obstet       Date:  1962-04

2.  Gastric infarction: a complication of selective vasopressin infusion.

Authors:  M Alves; V Patel; E Douglas; E Deutsch
Journal:  Dig Dis Sci       Date:  1979-05       Impact factor: 3.199

3.  Regional vascular effects of vasopressin: plasma levels and circulatory responses.

Authors:  P G Schmid; F M Abboud; M G Wendling; E S Ramberg; A L Mark; D D Heistad; J W Eckstein
Journal:  Am J Physiol       Date:  1974-11

4.  Pitressin-induced myocardial injury and depression in a young woman.

Authors:  B M Beller; A Trevino; E Urban
Journal:  Am J Med       Date:  1971-11       Impact factor: 4.965

Review 5.  Vasopressin as vasopressor.

Authors:  S R Goldsmith
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

6.  Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension.

Authors:  P Mols; R Hallemans; M Van Kuyk; C Melot; P Lejeune; H Ham; F Vertongen; R Naeije
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

7.  Hyposensitivity to vasopressin in a hemorrhaged-transfused rat model of portal hypertension.

Authors:  D Kravetz; S A Cummings; R J Groszmann
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

8.  Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension.

Authors:  R J Groszmann; D Kravetz; J Bosch; M Glickman; J Bruix; J Bredfeldt; H O Conn; J Rodes; E H Storer
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

9.  How the lower oesophageal sphincter affects submucosal oesophageal varices.

Authors:  J Miskowiak
Journal:  Lancet       Date:  1978-12-16       Impact factor: 79.321

10.  Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial.

Authors:  D Westaby; B R Macdougall; R Williams
Journal:  Hepatology       Date:  1985 Sep-Oct       Impact factor: 17.425

View more
  1 in total

1.  Recent advances in endovascular techniques for management of acute nonvariceal upper gastrointestinal bleeding.

Authors:  Romaric F Loffroy; Basem A Abualsaud; Ming D Lin; Pramod P Rao
Journal:  World J Gastrointest Surg       Date:  2011-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.